Lytix Biopharma AS

Research Lytix Biopharma AS (LYTIX) on Bullrun: market cap NOK 576.75M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerLYTIX
ExchangeOL
CountryNorway
SectorHealthcare
IndustryBiotechnology
CurrencyNOK
Market capNOK 576.75M
Financial periodQ1 2026
RevenueNOK 0
Net income-NOK 25.95M
Free cash flow-NOK 28.76M

Valuation Snapshot

latest market cap is NOK 576.75M.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	NOK 0	-NOK 59.97M	-NOK 59.85M	n/a	-0.87	NOK 9.89M	NOK 2.20M	NOK 61.75M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-23	NOK 576.75M	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 NOK.

About Lytix Biopharma AS

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab.

Related stock research

Norway stocks Norway Healthcare stocks A-Z stock index

Other Healthcare stocks

Selvaag Bolig ASA (0Q92) Aqua Bio Technology ASA (ABTEC) Arcticzymes Technologies ASA (B4V) Circio Holding ASA (CRNA) Exact Therapeutics AS (EXTX) Nykode Therapeutics ASA (NYKD) Oncoinvent ASA (ONCIN) SoftOx Solutions AS (SOFTX) Thor Medical ASA (TRMED) Zelluna ASA (ZLNA) Medistim ASA (0OCD) NORDHEALTH AS NK 1 (6E5)

Frequently asked questions

What is Lytix Biopharma AS's market cap?

Lytix Biopharma AS's market capitalization is NOK 576.75M.